4893
Noile-Immune Biotech Inc.
ノイルイミューン・バイオテック
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2023
316,818
Dec 2024
7,587
Dec 2025
5,000
Operating profit(thousand JPY)
Dec 2023
-775,391
Dec 2024
-1,069,183
Dec 2025
-797,255
Operating profit margin(%)
Dec 2023
-244.74
Dec 2024
-14,092.3
Dec 2025
-15,945.1
Profit before tax(thousand JPY)
Dec 2023
-1,127,594
Dec 2024
-962,035
Dec 2025
-791,116
Profit(thousand JPY)
Dec 2023
-1,130,014
Dec 2024
-964,455
Dec 2025
-793,536
Total assets(thousand JPY)
Dec 2023
5,778,946
Dec 2024
4,800,172
Dec 2025
4,011,579
Cash and cash equivalents(thousand JPY)
Dec 2023
5,555,691
Dec 2024
4,670,939
Dec 2025
3,918,321
Cash flows from operating activities(thousand JPY)
Dec 2023
-873,076
Dec 2024
-887,809
Dec 2025
-752,219
Cash flows from investing activities(thousand JPY)
Dec 2023
-5,316
Dec 2024
557
Dec 2025
-378
Cash flows from financing activities(thousand JPY)
Dec 2023
1,913,086
Dec 2024
2,500
Dec 2025
-20
Return on equity(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2023
98.3
Dec 2024
98.3
Dec 2025
97.8
Earnings per share(JPY per share)
Dec 2023
-27.25
Dec 2024
-22.28
Dec 2025
-18.33
Net assets per share(JPY per share)
Dec 2023
131.26
Dec 2024
108.97
Dec 2025
90.65
Dividend per share(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.